DeepLife

DeepLife is a drug discovery technology company that builds digital twins of cells using deep learning applied to multi-omics data. By computationally modeling cellular behavior at a fundamental level, DeepLife enables researchers and biopharmaceutical organizations to understand, predict, and engineer how cells function — accelerating the path from biological insight to therapeutic development.

The company's core mission is to map life one cell at a time, providing a powerful computational foundation for drug discovery teams seeking to move beyond traditional trial-and-error approaches and leverage AI-driven cellular modeling to identify and validate targets more efficiently.

Core Platform: TwinCell

• TwinCell is DeepLife's flagship product, offering a digital twin representation of cells built on deep learning and multi-omics data integration
• Designed to model and simulate cellular behavior, enabling researchers to explore biological hypotheses computationally before committing to costly wet-lab experiments
• Supports the engineering of cell behavior, making it applicable to target identification, mechanism-of-action studies, and therapeutic design

Underlying Technology

• DeepLife harnesses deep learning methodologies specifically trained on multi-omics data, capturing the complexity of biological systems across genomic, transcriptomic, proteomic, and related data layers
• The platform is built to translate large-scale biological data into actionable, predictive models of cellular states and responses
• An API is available, allowing external teams and platforms to integrate DeepLife's cellular modeling capabilities directly into their own drug discovery workflows and computational pipelines

Applications and Audience

• Primarily serves drug discovery organizations, including pharmaceutical and biotechnology companies seeking to accelerate and de-risk early-stage research
• Enables scientific teams to efficiently engineer cellular behavior, supporting use cases ranging from disease modeling to the identification of novel therapeutic interventions
• Open to scientific collaboration partnerships, reflecting the company's engagement with the broader research community